STAT Plus: For a Chinese cancer drug developer, Bristol-Celgene deal is poised to have big ripple effects

By REBECCA ROBBINS

IMAGINECHINA VIA AP

Like other leaders of China’s biotech sector, BeiGene is positioning itself as a global company, with ambitions to export drugs to the rest of the world.

https://www.statnews.com/2019/02/13/for-a-chinese-cancer-drug-developer-bristol-celgene-deal-is-poised-to-have-big-ripple-effects/?utm_source=STAT+Newsletters&utm_campaign=accddb5c8f-Cancer_Briefing&utm_medium=email&utm_term=0_8cab1d7961-accddb5c8f-149692869

READ MORE